Sugi Predict

Sugi Predict / Targets / ITGB1

ITGB1

Integrin beta-1 · P05556 · ITGB1 on Sugi Atlas →

83,689 patent compounds predicted against ITGB1, 42,703 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL84711 SCHEMBL84711 0.88 20/20
SCHEMBL92407 SCHEMBL92407 0.88 20/20
SCHEMBL84713 SCHEMBL84713 0.88 20/20
SCHEMBL85320 SCHEMBL85320 0.88 20/20
SCHEMBL85446 SCHEMBL85446 0.87 20/20
SCHEMBL84715 SCHEMBL84715 0.85 20/20
SCHEMBL84854 SCHEMBL84854 0.85 20/20
SCHEMBL85158 SCHEMBL85158 0.85 20/20
SCHEMBL85443 SCHEMBL85443 0.85 20/20
SCHEMBL92243 SCHEMBL92243 0.84 20/20
SCHEMBL84974 SCHEMBL84974 0.84 20/20
SCHEMBL84975 SCHEMBL84975 0.84 20/20
SCHEMBL85258 SCHEMBL85258 0.84 20/20
SCHEMBL85348 SCHEMBL85348 0.84 20/20
SCHEMBL85418 SCHEMBL85418 0.84 20/20
SCHEMBL85648 SCHEMBL85648 0.84 20/20
SCHEMBL85342 SCHEMBL85342 0.84 20/20
SCHEMBL85254 SCHEMBL85254 0.83 20/20
SCHEMBL85337 SCHEMBL85337 0.83 20/20
SCHEMBL84968 SCHEMBL84968 0.83 20/20

Clinical trials — most relevant to ITGB1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
68 Ga-NODAGA-E[c(RGDγK)]2: Positron Emission Tomography Tracer for Imaging of Angiogenesis in Ischemic Heart Disease PHASE2UNKNOWN
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer PHASE1/PHASE2COMPLETED
Safety and Efficacy of TollB-001 Tablets in Moderate to Severe Rheumatoid Arthritis PHASE2RECRUITING
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I PHASE1WITHDRAWN
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors PHASE1COMPLETED
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption PHASE1COMPLETED
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis EARLY_PHASE1UNKNOWN
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis EARLY_PHASE1UNKNOWN
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors EARLY_PHASE1NOT_YET_RECRUITING
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction EARLY_PHASE1UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke EARLY_PHASE1UNKNOWN
Angiogenesis and Fibrosis in Aortic Stenosis nanCOMPLETED
Angiogenesis and Fibrosis in Myocardial Infarction nanCOMPLETED
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer nanUNKNOWN
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS) nanCOMPLETED
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer nanCOMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis nanUNKNOWN
The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer nanUNKNOWN
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis nanCOMPLETED
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types nanCOMPLETED
Markers of Vascular Calcification in Diabetic Nephropathy in Patients With Diabetic Nephropathy nanUNKNOWN
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications nanCOMPLETED
Integrin αvβ6-targeted PET in Malignant Tumors nanRECRUITING
Serum Talin-1 and Cripto-1 in Colorectal Cancer nanNOT_YET_RECRUITING
Role of CD11a in Pathogenesis of Primary ITP and Effect of Immunosuppressive Therapy on Its Level nanCOMPLETED
Performance of 177Lu-PSMA-I&T for RLT in mCRPC - Prospective Multicenter Swiss Registry Study nanCOMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage nanCOMPLETED
Clinical Study of 18F-FAPI-RGD in Breast Tumors nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a ITGB1 binder may also engage these)

ProteinNameSimilarity
Q5RCA9 — 1.000 Q5RCA9 →
P12607 — 1.000 P12607 →
P53712 — 1.000 P53712 →
A5Z1X6 — 1.000 A5Z1X6 →
P12606 — 1.000 P12606 →
Q9GLP0 — 1.000 Q9GLP0 →
P53713 — 1.000 P53713 →
P11584 — 1.000 P11584 →
B0FYY4 — 1.000 B0FYY4 →
P09055 — 1.000 P09055 →
P49134 — 0.999 P49134 →
Q27874 — 0.998 Q27874 →
Q5VI41 — 0.998 Q5VI41 →
P07228 — 0.997 P07228 →
P32592 — 0.993 P32592 →
P11835 — 0.992 P11835 →
P53714 — 0.992 P53714 →
ITGB2 Integrin beta-2 0.992 landscape →
Q6ECI6 — 0.991 Q6ECI6 →
Q2VJ42 — 0.990 Q2VJ42 →
Q21313 — 0.987 Q21313 →
Q10743 — 0.987 Q10743 →
A2A863 — 0.987 A2A863 →
P11046 — 0.986 P11046 →
Q27591 — 0.984 Q27591 →
P18563 — 0.984 P18563 →
P24348 — 0.984 P24348 →
P85841 — 0.983 P85841 →
MMP2 72 kDa type IV collagenase 0.983 landscape →
Q9Z218 — 0.983 Q9Z218 →